DIFFERENTIAL EFFECT OF CIGARETTE-SMOKING ON ANTIPYRINE OXIDATION VERSUS ACETAMINOPHEN CONJUGATION

被引:15
作者
SCAVONE, JM
GREENBLATT, DJ
LEDUC, BW
BLYDEN, GT
LUNA, BG
HARMATZ, JS
机构
[1] TUFTS UNIV,NEW ENGLAND MED CTR,DIV CLIN PHARMACOL,BOX 1007,171 HARRISON AVE,BOSTON,MA 02111
[2] TUFTS UNIV,SCH MED,DEPT PSYCHIAT,DIV CLIN PHARMACOL,BOSTON,MA 02111
[3] TUFTS UNIV,SCH MED,DEPT PHARMACOL & MED,DIV CLIN PHARMACOL,BOSTON,MA 02111
关键词
Acetaminophen; Antipyrine; Cigarette smoking; Conjugation; Drug metabolism; Oxidation;
D O I
10.1159/000138644
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The effect of cigarette smoking on drug oxidation and conjugation was studied using antipyrine and acetaminophen as marker compounds. For the antipyrine study, healthy cigarette smokers (n = 30) and nonsmoking controls (n = 53) received a single 1.0-gram intravenous dose of antipyrine. For the acetaminophen study, 14 smokers and 15 nonsmokers received a 650-mg intravenous dose of acetaminophen. The clearance of antipyrine was significantly increased (0.93 vs. 0.60 ml/min/kg. p < 0.0001) and elimination half-life was correspondingly reduced (8.9 vs. 13.0h, p < 0.0001) in smokers compared to nonsmoking controls. Total recovery of antipyrine and metabolites excreted in urine did not differ between groups, but there was a significantly increased fractional clearance of antipyrine via formation of 4-hydroxyantipyrine and 3-hydroxymethy] metabolites in smokers. Fractional clearance via formation of norantipyrine did not differ significantly between groups. Comparison of acetaminophen kinetics between smokers and nonsmokers indicated no significant differences in elimination half-life, clearance or volume of distribution. Thus, cigarette smoking is more likely to induce drug oxidation rather than drug conjugation. However, not all oxidative pathways are equally influenced; induction effects of smoking are highly substrate selective and pathway specific. © 1990 S. Karger AG, Basel.
引用
收藏
页码:77 / 84
页数:8
相关论文
共 48 条
[1]  
ABERNETHY DR, 1985, J PHARMACOL EXP THER, V234, P345
[2]  
ABERNETHY DR, 1983, J PHARMACOL EXP THER, V224, P508
[3]  
ABERNETHY DR, 1983, J LAB CLIN MED, V101, P873
[4]   THEOPHYLLINE AND ANTIPYRINE DISPOSITION IN SMOKING AND NON-SMOKING EPILEPTIC SUBJECTS [J].
ACHESON, DWK ;
UDEN, S ;
BRAGANZA, JM ;
BROWN, SW ;
HOUSTON, JB .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1987, 24 (06) :812-815
[5]   HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC DETERMINATION OF ACETAMINOPHEN IN PLASMA - SINGLE-DOSE PHARMACOKINETIC STUDIES [J].
AMEER, B ;
GREENBLATT, DJ ;
DIVOLL, M ;
ABERNETHY, DR ;
SHARGEL, L .
JOURNAL OF CHROMATOGRAPHY, 1981, 226 (01) :224-230
[6]   LARGE THEOPHYLLINE REQUIREMENTS DUE TO HIGH THEOPHYLLINE CLEARANCE - VERIFICATION BY THE ANTIPYRINE TEST [J].
BLYDEN, GT ;
LEDUC, BW ;
GREENBLATT, DJ .
PHARMACOLOGY, 1986, 32 (04) :226-231
[7]   PARACETAMOL AS A TEST DRUG TO DETERMINE GLUCURONIDE FORMATION IN MAN - EFFECTS OF INDUCERS AND OF SMOKING [J].
BOCK, KW ;
WILTFANG, J ;
BLUME, R ;
ULLRICH, D ;
BIRCHER, J .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1987, 31 (06) :677-683
[8]   COMPARISON OF THE INVIVO AND INVITRO RATES OF FORMATION OF THE 3 MAIN OXIDATIVE METABOLITES OF ANTIPYRINE IN MAN [J].
BOOBIS, AR ;
BRODIE, MJ ;
KAHN, GC ;
TOVERUD, EL ;
BLAIR, IA ;
MURRAY, S ;
DAVIES, DS .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1981, 12 (06) :771-777
[9]  
BRANCH RA, 1982, HEPATOLOGY, V2, P97